WCLC 2025 - Posters & ePosters-EP.12.24 Common vs Uncommon EGFR Mutations in NSCLC and the Potential Prognostic Role of Neutrophil-To-Lymphocyte Ratio

EP.12.24 Common vs Uncommon EGFR Mutations in NSCLC and the Potential Prognostic Role of Neutrophil-To-Lymphocyte Ratio

Pdf Summary

This retrospective study analyzed 50 patients with EGFR-mutated non-small cell lung cancer (NSCLC) to evaluate survival differences between common and uncommon EGFR mutations and to assess the prognostic role of baseline neutrophil-to-lymphocyte ratio (NLR). Patients were predominantly stage III-IV (86%), with a median age of 64 years. The common mutations included exon 21 p.Leu858Arg (30%) and exon 19 p.Glu746_Ala750del (20%), while several uncommon mutations such as exon 19 p.Ala750Pro and exon 20 p.Ser768_Asp770dup were also observed.<br /><br />Overall survival (OS) did not significantly differ between common (median OS 32.0 months) and uncommon mutation groups (31.5 months; p=0.895). However, integrating NLR stratification revealed significant prognostic implications. Patients with common EGFR mutations and high baseline NLR (≥2.8) had markedly poorer OS (5.2 months) compared to those with low NLR (<2.8) who showed much longer survival (66.3 months). Similarly, in the uncommon mutation cohort, high NLR was associated with worse OS (26.2 months), whereas low NLR patients had median OS not reached (p=0.011).<br /><br />The study concludes that while mutation subtype alone does not predict survival differences, combining mutation status with NLR—an accessible marker of systemic inflammation—offers meaningful prognostic stratification in advanced NSCLC. High NLR correlates with poorer outcomes, especially in patients with common EGFR mutations. Thus, NLR may serve as a valuable complementary biomarker alongside EGFR mutation analysis to better guide therapeutic decisions.<br /><br />Future research is encouraged to validate NLR's utility in clinical practice and investigate how this inflammation marker might enhance personalized treatment for EGFR-mutated NSCLC patients. This integrated approach could optimize prognostication and treatment planning in this patient population.

Asset Subtitle

Javier Baena

Meta Tag

Speaker Javier Baena

Topic Metastatic Non-small Cell Lung Cancer – Targeted Therapy

Keywords

EGFR-mutated NSCLC

non-small cell lung cancer

common EGFR mutations

uncommon EGFR mutations

neutrophil-to-lymphocyte ratio

baseline NLR

overall survival

prognostic biomarker

systemic inflammation

advanced lung cancer